Intertypic vaccine/vaccine recombinant polioviruses are frequently isolated from vaccine-associated paralytic poliomyelitis cases (VAPP). We identified a vaccine/ nonvaccine poliovirus recombinant as the causative agent of a lethal VAPP. Partial RNA sequencing revealed a tripartite recombinant structure of the viral genome. This consisted of a central capsid core of vaccine origin flanked by two units of nonvaccine origin. The first nonvaccine genomic unit spanned the whole 5' noncoding region, and the second one almost the entire nonstructural protein-coding region and the 3' noncoding region. Amino acid and nucleotide sequence similarities in the 3' and 5' unidentified regions indicated that the viral donor(s) were poliovirus species, suggesting recombination between a vaccine-derived and a wild poliovirus. The nonvaceine donor(s) could not be identified among the investigated wild polioviruses cocirculating in the same geographical area. This is the first report of a natural recombination event occurring in the 5' genomic extremity of poliovirus. The neurovirulence for transgenic mice and the pathogenicity for humans of the recombinant suggested that the modular genomic organization of this virus might have conferred a selective advantage over its vaccine parent.
Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus
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The genetic variability of picornaviruses is mostly due to nucleotide substitutions resulting from a high error frequency during the replication of viral RNA (Holland et al., 1982) . Genetic change in poliovirus can also occur by molecular recombination (Cooper, 1977; Lai, 1992) . Genetic recombination of poliovirus vaccine (Sabin) strains has been demonstrated (Kew & Nottay, 1984; Macadam et al., 1989; Lipskaya et al., 1991) and is even frequent (Furione et al., 1993) in strains isolated from vaccine-associated paralytic poliomyelitis cases (VAPP). Viral donors for the recombined genotypes described were of vaccine origin. The possibility of recombination between vaccine and wild polioviruses has been previously proposed (Rico-Hesse et al., 1987) but the supposed candidate virus has not been studied in detail. In a previous study (Furione et al., 1993) , 11 of the 36 recombinant vaccine-derived viruses analysed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) differed markedly from the three vaccine strains in the 3D polymerase (3D p°~) coding region, suggesting that the virus donor for this part of the genome could be a wild poliovirus or even a non-polio enterovirus.
In a previous study (Georgescu et al., 1994) , we described a VAPP case (named 2-1) recorded in Romania, in 1980. Three isolates were obtained from this * Author for correspondence. Fax + 33 1 45 68 87 80. e-mail mariuta @ pasteur.fr patient, one from stool (2-Is) and two from the central nervous system (obtained at necropsy): spinal cord (2-Ic) and medulla (2-Ic'). A preliminary analysis with polyclonal sera and intratypic differentiation using monoclonal antibodies showed that all three isolates were type 2 vaccine-derived strains (Georgescu et al., 1994) . The genotype of the 2-I strains was investigated by analysing the recombination pattern using the previously described double RFLP method (Furione et al., 1993) . The viral RNA was reverse transcribed using avian myeloblastosis virus reverse transcriptase and random hexanucleotides (Georgescu et al., 1994) and fragments of the structural protein VP1 and the 3D p°l coding regions were amplified by PCR. The DNA products were cleaved by suitable restriction endonucleases and analysed on agarose gel (RFLP test). This RFLP test allows the identification and differentiation of the three vaccine strains (Fig. 1) . The RFLP pattern in the VP1 coding region (RFLP-1) of the 2-I strains was similar to that of the vaccine Sabin 2 strain, confirming the vaccine origin of the 2-I strains. The RFLP pattern of the 3D p°l coding region (RFLP-3D) was different from that of the three poliovirus vaccine strains. This suggested that the 2-I vaccinederived strains were either recombinants with a 3' genomic region of nonvaccine origin or had highly modified vaccine-derived sequences in this region. Moreover, an attempt to amplify by PCR a fragment in the 5' noncoding region of the 2-I strains with Sabin 2-specific primers failed.
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We further investigated the 2-Is and 2-Ic strains by R N A sequencing (Fichot & Girard, 1990) . The viral genome of strain 2-Is was scanned by partial sequencing in most of the viral regions, including the 5' noncoding and 3' noncoding regions (5'NCR and 3'NCR, respectively), the capsid protein-coding regions and some of the nonstructural protein-coding regions (fragments a to k in Fig. 2A ). For strain 2-Ic, we sequenced some genomic regions (fragments b, c, f, g and k in Fig. 2A ) to confirm its identity with the strain isolated from stool (2-Is). These two strains were identical in all the sequenced fragments except for one nucleotide difference (position 2910). We aligned the nucleotide sequences of the 2-I strains with the corresponding sequences of the three vaccine Sabin strains and calculated in each case the degree of nucleotide sequence identity.
Strain 2-Is and the vaccine Sabin 2 strain were 100 % identical along the sequenced genomic segments (nucleotide positions 1004-1142 and 1723-1856) in the VP2 and VP3 capsid protein-coding regions. In the sequenced segment of the VP1 coding region (nucleotide positions 2820-2939), the 2-Is sequence was similar to that of Sabin 2 except for an U ~ C substitution which was found at position 2909. This missense mutation in the VP1 region (Ilelaa--+ Thr) is frequently encountered in type 2 vaccine-derived strains (Macadam et al., 1993) . This mutation, with that at nucleotide position 481 in the 5 ' N C R is essential for reversion of the Sabin 2 vaccine noncoding region (5'NCR), structural capsid protein (VP4 to VP1) and nonstructural protein (2A to 3D) coding regions and the 3' noncoding region (3'NCR). Restriction profiles for the Sabin 1, 2 and 3 strains (S1, $2 and $3 respectively) and the 2-I VAPP case isolates from stool (2-Is) and central nervous system (2-Ic and 2-Ic') are shown for each of the two amplified fragments. The restriction endonucleases used are indicated for each gel. strain towards neurovirulence (Ren et al., 1991; Macadam et al., 1993) .
There were numerous differences between strains 2-I (2-Is and 2-Ic) and the Sabin 2 strain in the 2A proteasecoding region downstream of position 3594 and in the region upstream of position 768, including part of the VP4 capsid protein-coding region and the 5 ' N C R ( Fig.  2A) . In these regions, the difference between the sequences of strains 2-I and Sabin 2 was as high as that between the different poliovirus serotypes (see below). It is more probable that these 2-I sequences were derived from a nonvaccine viral strain rather than from a mutated form of the Sabin 2 vaccine strain. Thus, the 2-I strains appear to be recombinant viruses with a tripartite genome formed of a central part derived from the vaccine type 2 strain and two extremities of nonvaccine origin (Fig. 2A) . The central part included the region coding for the capsid proteins and the Nterminal half of the 2A protease (from amino acid 8 of VP4 to amino acid 69 of 2A).
We tried to identify the viral parent of the 5' and 3' genomic regions of the 2-I strains. First, we attempted to assign it to a wild poliovirus or to a non-polio enterovirus by comparing amino acid and nucleotide sequences of the 2-I strains to those of other known polioviruses (PV1/Sabin, PV2/Sabin, PV3/Sabin, PV2/Lansing and PV3/Finland/84) and non-polio enteroviruses.
Amino acid sequences were deduced from the segments of the 3' region of the 2-Is strain (h, i, j, k in Fig. 2A ) and were very similar to the corresponding sequences of polioviruses (equal or more than 97"9 %). The non-polio enteroviruses most similar to polioviruses in the nonstructural protein-coding region are the coxsackieviruses A21 (CA21) and A24 (CA24) (Hughes et al., 1989; Supanaranond et al., 1992) . We compared the amino acid sequence of the 2-Is strain to those of CA21 and CA24 in a region where the coxsackieviruses differ from polioviruses: the C-terminal part of the 2C protein (amino acids 173-268) (Fig. 2B ). In this region the 2-Is strain was 97.9-98.9 % identical to the polioviruses, and only 79.1% and 82.3% identical to CA21 and CA24, respectively (Fig. 2B ). These findings strongly support a wild poliovirus origin for the 3' end of the 2-I strains.
The 5' fragment from the N-terminal part of the VP4 capsid protein of the 2-I strains, which is apparently of non-Sabin origin, encodes only seven amino acids. The deduced sequence of these amino acids was identical to those of other polioviruses and CA24 but different from that of CA21. The nucleotide sequence identity between polioviruses and CA21 or CA24 in the 5'NCR is very high, such that they cannot be differentiated on the basis of these sequences. However, CA 24 differs from the polioviruses by the presence of a four poly(A) stretch beginning at nucleotide position 120. This poly(A) stretch was absent from the 2-Is strain. All these observations suggested that the 5' end of the 2-I strains also originated from wild poliovirus.
The 2-I strains were isolated in Romania during outbreaks of poliomyelitis due to wild polioviruses (Crainic et al., 1992) . We therefore investigated whether the recombination donor was one of these wild polioviruses. In Romania, poliomyelitis has been successfully controlled since 1960 by the use of the trivalent oral poliovirus vaccine (OPV). Following the replacement in 1978 of the trivalent OPV with a monovalent type 1 OPV, there were two outbreaks of poliomyelitis with wild-type 2 and type 1 viruses between 1980-1982. Wildtype 3 viruses displaying high nucleotide sequence similarity (data not shown) were also isolated in 1980 from three cases. Three wild poliovirus strains, one representative of each serotype, isolated at the beginning of the epidemics in the same year as the 2-I strains (1980) were examined (wl/1980, w2 and w3). The type 1 (wl/1980) and type 2 (w2) wild strains had RFLP profiles in the VP1 coding region identical to those of other type 1 or 2 wild strains from the same epidemics (Balanant et al., 1991) , suggesting that they were representative of the circulating type 1 or 2 wild genotype. We compared the nucleotide sequences of the recombinant 2-I strains with those of the three wild strains (Fig. 2C) . The nucleotide sequence identity between the 2-I strains and these wild poliovirus strains was relatively low along both regions analysed (nucleotide positions 446-535 in the 5'NCR and 7257-7345 in the C-terminal part of the 3D p°l coding region, Fig. 2C ). This indicated that the wild strains investigated were not the donors of the recombinant 2-I strains. Nevertheless, we could not exclude the presence of the wildtype parent among other, co-circulating polioviruses that were not investigated. Alternatively, the parent may have been displaced from the population by the epidemic wild strains (wl/1980, w2) which possibly had a better ability to establish intestinal infection. The 2-I strains could also have been imported as such from another geographical area. All these possible epidemiological relationships have been previously described in a study of 62 wild-type 1 isolates (Rico-Hesse et al., 1987) .
We report a vaccine/nonvaccine recombinant virus confirming the fact that poliovirus vaccine strains can recombine not only with each other but also with wild polioviruses (Rico-Hesse et al., 1987 ). An explanation for such a recombination event is that recombinants rapidly acquire some selective advantages which would permit their adaptation to different environments (Lai, 1992) . The 2-I recombinant has lost the thermosensitive and the attenuated phenotype (as tested in transgenic mice sensitive to poliovirus) of the Sabin 2 parent (Georgescu et al., 1994) . Moreover, it was highly pathogenic for humans, since it induced lethal poliomyelitis. Both clinically and epidemiologically, this vaccine/nonvaccine recombinant poliovirus behaved as a wild poliovirus. Thus, vaccine/nonvaccine recombination should be considered as another possible means by which vaccine strains can revert to virulence. When the appropriate conditions are fulfilled (co-infection with vaccine and wild strains), the vaccine/wild recombination might be an important mechanism of conversion, other than point mutations, to the wild phenotype. Apparently, the vaccine-derived unit of the 2-I virus did not interfere with the replicative ability of the virus. It might, however, have constituted an antigenic obstacle to its spread in a population immunized with the OPV. This might explain the isolation of the 2-I virus in only one VAPP case.
The genomic structure of the 2-I recombinant virus has two peculiarities. The first is that it contains a recombination junction in the 5' extremity of the genome and, to our knowledge, this is the first report of this phenomenon. Generally, the recombination junctions, whether single (Lipskaya et al., 1991) or multiple (Cammack et al., 1988; Macadam et al., 1989; Georgescu et al., 1994) for natural poliovirus recombinants map in the nonstructural coding region of the viral genome. Here we show that poliovirus can recombine in the 5' extremity and not only in the nonstructural proteincoding region. This is not surprising, knowing that, for the three serotypes of poliovirus the major determinants of attenuation map in the 5'NCR (Kawamura et al., 1989; Westrop et al., 1989; Ren et al., 1991) and that recombination with a wild virus might generate a new, more fit phenotype. The second peculiarity of this virus is the simultaneous presence of wild-type sequences in the 5'NCR and in the 3' genomic extremity, comprising almost all of the nonstructural protein-coding region and the two NCRs. It is unclear whether there were one or more recombination steps. Epidemiologically, it seems likely that the 5' and 3' unidentified subgenomic regions originated from a single donor. However, a two-donor hypothesis cannot be discarded. The double recombinant virus could have emerged after an infection with different viruses in the same individual or after several interhuman passages since the 2-1 strains were collected from a contact VAPP case, attesting to at least one interhuman passage. The recombination could have occurred stochastically but an attractive scenario might be that the double recombinant was selected as an answer to some structural or functional viral requirements. In the hypothesis of a single donor, the interactions between the nonstructural proteins and the 5'NCR might prove to be more efficient in a homologous context. The modular assembly of the virus could also respond to some structural constraints. It has been recently shown that the 5' and 3' ends may come in close contact in the secondary structure folding of the poliovirus genomes (A. Palmenberg, personal communication).
The integrity of the capsid region of polioviruses seems to be important. This has been suggested by two in vitro studies on intertypic recombinant chimera which were shown to be nonviable when the recombination junctions were located in the capsid-coding region (Stanway et al., 1986; Kohara et al., 1988 ). An intratypic chimeric recombinant with a recombination junction in the capsidcoding region was also shown to be unstable compared to its parental strains (Kohara et al., 1985) . Chimeric intertypic recombinant viruses containing entire heterologuous capsid coding regions have been proposed as candidates for the live OPV (Kohara et al., 1988; Nomoto, 1993) . One of the properties required for their validation as vaccines is the ability to multiply extensively in the human gut. Here we showed that a tripartite poliovirus very similar in organization to the chimeric vaccine candidates, although a vaccine/wild recombinant, replicated well in the human gut.
